Pricing Log in Create free account

DiaMedica Therapeutics, Inc. (DMAC) vs ARS Pharmaceuticals, Inc. (SPRY)

DiaMedica Therapeutics, Inc. and ARS Pharmaceuticals, Inc. are both Biotechnology companies. DiaMedica Therapeutics, Inc. and ARS Pharmaceuticals, Inc. are of similar size ($433.6M and $404.8M). DiaMedica Therapeutics, Inc. has the higher net margin (0.00% vs −184.3%) and the higher return on invested capital (0.00% vs −335.7%). Across the 14 metrics below, DiaMedica Therapeutics, Inc. leads on 11 and ARS Pharmaceuticals, Inc. on 3.

Valuation

Metric DMAC SPRY Biotechnology median
P/E n/m n/m 8.50
P/S n/m 3.37 9.71
P/B 10.68 31.51 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 3.61 9.21
Earnings yield (9.47%) (54.91%) (33.15%)
Free cash flow yield (7.70%) (53.80%) (25.50%)

Profitability

Metric DMAC SPRY Biotechnology median
Gross margin 0.00% 71.37% 65.16%
Operating margin 0.00% (184.96%) 0.00%
Net margin 0.00% (184.26%) 0.00%
Free cash flow margin 0.00% (167.97%) 0.00%
Return on equity (114.62%) (210.37%) (56.36%)
Return on assets (98.18%) (76.54%) (48.04%)
Return on invested capital 0.00% (335.65%) 0.00%

Growth

Metric DMAC SPRY Biotechnology median
Revenue growth (TTM) — 4.08% 6.02%
EPS growth (last fiscal year) (16.67%) (2,275.00%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMAC SPRY Biotechnology median
Debt to equity 0.00 13.72 0.00
Current ratio 6.72 3.48 4.72
Net debt to EBITDA 1.70 0.42 0.96

Dividend

Metric DMAC SPRY Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DMAC SPRY Biotechnology median
Market cap 433.56m 404.75m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack